Hepatology Research

Article	Citations
Reply to Letter to the Editor: Regarding the “Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy”	208
Efficacy and Safety of Direct Oral Anticoagulants in Budd–Chiari Syndrome After Percutaneous Recanalization	66
Deceased Donation Disparities in East Asia—A Tale of Two Systems	65
Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child–Pugh A categ	52
Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study	47
Initial Experience With Nalmefene in Alcohol‐Related Liver Disease: A Real‐World Retrospective Study	41
Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma	40
Development and validation of a prognostic model for 90‐day survival in patients with alcohol‐associated cirrhosis and acute decompensation	37
Role of PAR1 −506 deletion/insertion polymorphism in primary sclerosing cholangitis	35
Reversion of liver cirrhosis after endovascular treatment in Chinese patients with Budd–Chiari syndrome	34
Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: how should we choose among these two latest and probably the last regimens?	31
Utility of Oncological Resectability Criteria in Recurrent Hepatocellular Carcinoma After Hepatectomy	27
Immune‐related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan	27
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs	25
The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases	25
Conditional recurrence analysis of intrahepatic cholangiocarcinoma: Changes in recurrence rate and survival after recurrence resection by disease‐free interval	25
Prognostic value of virtual portal pressure gradient response in compensated cirrhotic patients treated with carvedilol	24
Rechallenge of Atezolizumab Plus Bevacizumab Therapy in Patients With Unresectable Hepatocellular Carcinoma	24
Acknowledgment	23
Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease	22
RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury	22
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	21
Prediction of intrahepatic covalently closed circular DNA levels in patients with resolved hepatitis B virus infection: Impact of serum antibody to hepatitis B core antigen titers	21
Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocel	21
The change from NAFLD to MAFLD expands fatty liver information flow	20

Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi‐Center Real‐World Study	19
Continuous Intravenous Infusion of Hepatocyte Growth Factor Promotes the Development of a Fibrolytic Phenotype in Hepatic Macrophages and Stellate Cells in a Rat Model of Bile Duct Ligation	19
Young Adults Are at Highest Risk of Liver Fibrosis and Mortality Associated With Steatotic Liver Disease With Metabolic Dysfunction and Alcohol Consumption	18
Transcriptomic and proteomic studies suggest the establishment of advanced zonation‐like profiles in human‐induced pluripotent stem cell‐derived liver sinusoidal endothelial cells and carboxypeptidase	18
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral re	18
Do Patients With Alcoholic Cirrhosis Accurately Recognize Their Alcohol Tolerance? A Study Comparing Self‐Perception and ALDH2/ADH1B Genotype	18
	17
Letter to the Editor: “Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disea	17
Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management	16
Issue Information	16
Issue Information	16
Issue Information	16
Magnetic resonance imaging‐based risk factors of hepatocellular carcinoma after direct‐acting antiviral therapy: A multicenter observational study	15
	15
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study	15
Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus‐related liver cirrhosis	15
What can we create by adding robotic assistance to conventional laparoscopic liver resection?	15
Chronic liver disease questionnaire to manage patients with chronic liver diseases	14
Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria	14
	13
Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis	13
Issue Information	13
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease	13
Metabolic Effect on Serum Mac‐2 Binding Protein Glycan Isomer Level and Its Normal Range in the Health Checkup Examinee	12
Autoimmune Hepatitis: Histopathological Diversity and Its Clinical Implications	12
Serial increase and high alpha‐fetoprotein levels predict the development of hepatocellular carcinoma in 6 months	12
The Nara Declaration: A New Collaborative Flow for Chronic Liver Disease Between Primary Care Physicians and Gastroenterologists/Hepatologists	12
	12
Post‐COVID‐19 Changes in Body Composition and Adiposity in Patients With Chronic Liver Disease: A Longitudinal Study From Japan	12
Differential peripheral memory T cell subsets sensitively indicate the severity of nonalcoholic fatty liver disease	12
Epidemiology of Fontan‐associated liver disease in Japan: Results from a nationwide survey in 2021	12
Molecular biological role of epithelial splicing regulatory protein 1 in intrahepatic cholangiocarcinoma	12
Issue Information	12
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis	12
Weighted thyroid‐stimulating hormone disturbance in prognosis of hepatitis B virus‐related acute‐on‐chronic liver failure	11
Moderate‐carbohydrate diet without caloric or lipid restriction for Japanese adult patients with nonalcoholic fatty liver disease: A prospective cohort study	11
Safety and effectiveness of SARS‐CoV‐2 vaccines for patients with intractable hepatobiliary diseases: A multicenter, questionnaire‐based, cross‐sectional study	11
Clinically relevant model of oxaliplatin‐induced sinusoidal obstruction syndrome	11
Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab	11
Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma	11
Quantitative evaluation of tumor signal heterogeneity on gadoxetic acid‐enhanced magnetic resonance imaging as a predictor of postoperative survival and antitumor immunity in hepatocellular carcinoma	11
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First‐Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi‐Center Retrospective Study	10
Measurement of spleen length and two‐dimensional spleen index is comparable to spleen volumetry by computed tomography for predicting esophageal varices	10
	10
The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafte	10
Early diagnosis of hepatic inflammation in Japanese nonalcoholic fatty liver disease patients using 3D MR elastography	10
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	10
Impact of muscle volume changes following atezolizumab‐bevacizumab therapy in patients with unresectable hepatocellular carcinoma	10
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	10
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	10

	10
Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor‐β signaling in their molecular effects	10
Cost‐effectiveness of hepatitis E virus vaccination strategy	9
Sex‐differences in the association of interleukin‐10 and interleukin‐12 variants with the progression of hepatitis B virus infection in Caucasians	9
Utilizing Altmetrics to Track Advancements in Noninvasive Tests for MASLD	9
Predictive model containing gene signature and shear wave elastography to predict patient outcomes after Kasai surgery in biliary atresia	9
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	9
HCV Elimination Strategies for Maximum Effectiveness, Tailored to National and Regional Circumstances	9
Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living‐donor liver transplantation: Single‐center controlled trial	9
	9
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	9
Aspirin Use and Mediterranean Diet Adherence as Factors Associated With Overall Mortality in Patients With MASLD in NHANES	9
Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation	8
Letter to the Editor: “Altered Serum Bile Acid Pattern as an Independent Factor for Covert and Overt Hepatic Encephalopathy in Patients With Cirrhosis”	8
Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study	8
Applying Cachexia Criteria to Cirrhosis: Considerations for Appropriate Interpretation and Future Research	8
	8
Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan	8
Comparison between splenic dispersion slope and splenic shear wave speed on ultrasound elastography for predicting esophageal varices	8
Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body	8
	8
Comment on “Individualized Prognostication Based on Deep‐Learning Models Using Computed Tomography as an Imaging Biomarker After Hepatocellular Carcinoma Resection”	8
Employment Status of Patients With Liver Disease: A Nationwide Questionnaire Survey in Japan	8
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	8
Evolution of Hepatocellular Carcinoma Treatment Outcomes Over Two Decades in Japan: Improvements in Early‐Stage Viral Disease	8
The role of the nervous system in liver diseases	8
Issue Information	8
	8
Immunovascular microenvironment in relation to prognostic heterogeneity of WNT/β‐catenin‐activated hepatocellular carcinoma	8
Cachexia and Type 2 Diabetes Mellitus Are Independent Factors for Mortality in Patients With Cirrhosis	7
Perturbation of Wnt/β‐catenin signaling and sexual dimorphism in non‐alcoholic fatty liver disease	7
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19	7
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	7
Real‐world efficacy of radiomics versus clinical predictors for microvascular invasion in patients with hepatocellular carcinoma: Large cohort study	7
Etiological changes of liver cirrhosis and hepatocellular carcinoma‐complicated liver cirrhosis in Japan: Updated nationwide survey from 2018 to 2021	7
Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease	7
Issue Information	7
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	7
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma	7
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan	7
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	7
Low syntaxin 17 expression in donor liver is associated with poor graft prognosis in recipients of living donor liver transplantation	7
Integrated policy of medical expense subsidies and clinical registry for patients with liver cancer and decompensated cirrhosis in Japan	7
Steroid administration for ischemic complications after radiofrequency ablation: A retrospective study	7
Erratum	7
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	7
Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis	7
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	7
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis	6
Cost‐effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China	6
Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease	6
Analysis of non‐severe acute onset autoimmune hepatitis according to the presence of radiological heterogeneity	6
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	6
Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy	6
Correlations Between Serum Bile Acids and Ammonia Levels in Patients With Cirrhosis	6
Issue Information	6
Impact of liver fibrosis on the relative abundance of a urease‐positive Streptococcus salivarius group from saliva in patients with chronic liver disease	6
Lipolysis‐Stimulated Lipoprotein Receptor Gene Variants as a Cause of Progressive Familial Intrahepatic Cholestasis: A Case Report	6
Lymphocyte‐to‐Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma	6
Issue Information	6
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	6
	6
Successful second‐line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal–epithelial transition factor amplification	6
A Pharmacovigilance Study of Immune Checkpoint Inhibitor‐Associated Cholangitis: Insights From the FDA Adverse Event Reporting System	6
High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma	6
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	6
Tamoxifen‐Induced Liver Injury in Patients With Breast Cancer: Frequency, Risk Factors and Clinical Course	6
	6
A nation‐wide medical record database study: Value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan	6
Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data	6
	6
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	6
Mitochondrial Oxidative Stress in Circulating Leukocytes as a Prognostic Marker in Hepatocellular Carcinoma	6
SOX9 Is a Key Factor for the Postnatal Maturation of the Intrahepatic Bile Duct Network	6
Cachexia in Cirrhosis Is Characterized by Sex‐Specific Loss of Muscle Mass and Adipose Tissue	6
Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups	5
Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis	5
Microwave Thermosphere Ablation Versus Radiofrequency Ablation in Hepatocellular Carcinoma: Optimizing Treatment Strategies for Tumor Size and Malignancy Grade	5
Mac‐2 Binding Protein Glycosylation Isomer as a Dynamic Biomarker in Obstructive Cholestasis	5
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	5

Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis	5
	5
Seroprevalence and incidence of hepatitis E virus infection in the general population of Iwate prefecture, Japan: A retrospective cohort study	5
Acknowledgment	5
Effects of weight loss on metabolic dysfunction‐associated fatty liver disease in Japanese people: Non‐alcoholic fatty liver disease in the Gifu area, longitudinal analysis study	5
Caution Regarding Short‐Term Increases in Ammonia Levels Following Splenic Artery Embolization	5
Refining Surgical Candidate Selection After Systemic Therapy in Advanced Hepatocellular Carcinoma	5
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	5
Clinical benefits of partial splenic embolization for cancer patients	5
Dried blood spot‐based host genome analysis technique targeting pathological associations with hepatitis B: Development and clinical application in the Cambodian population	5
Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy	5
Fibroblast growth factor receptor 2 alterations in intrahepatic cholangiocarcinoma: Prevalence and clinical implications in Asian populations	5
The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: A study based on magnetic resonance elastography	5
Advancing Gene Mutation Analysis Through Post‐Ablation Liver Tumor Biopsy Specimens	5
High serum growth differentiation factor 15 is a risk factor for the occurrence of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs	5
Evaluation of diagnostic criteria for mild‐to‐advanced stages of Fontan‐associated liver disease: A nationwide epidemiological survey in Japan	5